RANTES Recombinant Antibody

$IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in HUVEC cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100 in HUVEC cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Breast Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Breast Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with CCL5 (6A1) Monoclonal Antibody (bsm-54125R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$THP-1 (H) cells were treated with or without PMA (100ng\/ml) for 48 h, and LPS (1ug\/ml) for 8 h, and Brefeldin A (600ng\/ml) for 3 h, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with RANTES monoclonal antibody, unconjugated (bsm-54125R) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

THP-1 (H) cells were treated with or without PMA (100ng\/ml) for 48 h, and LPS (1ug\/ml) for 8 h, and Brefeldin A (600ng\/ml) for 3 h, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with RANTES monoclonal antibody, unconjugated (bsm-54125R) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
IHC-P
IHC-F
IF
ICC/IF

Reactivity

Human

Overview
Catalog #	bsm-54125r
Product Name	RANTES Recombinant Antibody
Applications	WB IHC-P IHC-F IF ICC/IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human RANTES
Clonality	Recombinant
Clone #	6A1
Isotype	IgG
Concentration	Lot Dependent
Purification	purified by Protein A.
Storage Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6352
Swiss Prot	P13501
Subcellular location	Secreted
Synonyms	D17S136E; RANTES; SCYA5; SIS-delta; SISd; TCP228; eoCP; CCL5_HUMAN; CCL5; Eosinophil chemotactic cytokine; Small-inducible cytokine A5; T cell-specific protein P228 (TCP228); T-cell-specific protein RANTES; C-C motif chemokine ligand 5; small inducible cytokine A5 (RANTES); chemokine (C-C motif) ligand 5; T-cell specific protein p288; T-cell specific RANTES protein; regulated upon activation, normally T-expressed, and presumably secreted; beta-chemokine RANTES; small inducible cytokine subfamily A (Cys-Cys), member 5
Background	Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils. May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IF
ICC/IF	1:50-100